ABEO vs. ADAG, LFVN, GLTO, GANX, LTRN, FIXX, IOBT, ENOB, CNTB, and ANEB
Should you be buying Abeona Therapeutics stock or one of its competitors? The main competitors of Abeona Therapeutics include Adagene (ADAG), LifeVantage (LFVN), Galecto (GLTO), Gain Therapeutics (GANX), Lantern Pharma (LTRN), Homology Medicines (FIXX), IO Biotech (IOBT), Enochian Biosciences (ENOB), Connect Biopharma (CNTB), and Anebulo Pharmaceuticals (ANEB). These companies are all part of the "pharmaceutical preparations" industry.
Abeona Therapeutics vs.
Adagene (NASDAQ:ADAG) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, media sentiment, community ranking, profitability and institutional ownership.
Adagene currently has a consensus price target of $5.00, indicating a potential upside of 275.94%. Abeona Therapeutics has a consensus price target of $40.00, indicating a potential upside of 995.89%. Given Abeona Therapeutics' higher possible upside, analysts clearly believe Abeona Therapeutics is more favorable than Adagene.
Abeona Therapeutics received 495 more outperform votes than Adagene when rated by MarketBeat users. However, 76.19% of users gave Adagene an outperform vote while only 71.17% of users gave Abeona Therapeutics an outperform vote.
In the previous week, Abeona Therapeutics had 6 more articles in the media than Adagene. MarketBeat recorded 6 mentions for Abeona Therapeutics and 0 mentions for Adagene. Abeona Therapeutics' average media sentiment score of 0.57 beat Adagene's score of 0.49 indicating that Abeona Therapeutics is being referred to more favorably in the news media.
Adagene has a beta of 0.05, suggesting that its share price is 95% less volatile than the S&P 500. Comparatively, Abeona Therapeutics has a beta of 1.27, suggesting that its share price is 27% more volatile than the S&P 500.
Abeona Therapeutics has lower revenue, but higher earnings than Adagene.
Adagene's return on equity of 0.00% beat Abeona Therapeutics' return on equity.
13.7% of Adagene shares are held by institutional investors. Comparatively, 37.7% of Abeona Therapeutics shares are held by institutional investors. 21.2% of Adagene shares are held by insiders. Comparatively, 2.4% of Abeona Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
Abeona Therapeutics beats Adagene on 8 of the 13 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ABEO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Abeona Therapeutics Competitors List
Related Companies and Tools